Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BO-112 IT Monotherapy and Combination with Anti-PD1 in Solid Tumors
NCT02828098Phase 1Completed
- Sponsor
- Highlight Therapeutics
- Start
- Jun 2016
- Primary completion
- Jul 2020
- Modality
- Oncolytic Viruses, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nanoplexed poly I:C in solid tumor (2 arms), sponsored by Highlight Therapeutics. Primary endpoint: Number of subjects with adverse events at 1 year. Started Jun 2016; status: completed.
02
Drugs
nanoplexed poly I:C
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02828098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02828098.